Halozyme Therapeutics, Inc.
Index- P/E15.38 EPS (ttm)2.52 Insider Own0.20% Shs Outstand137.94M Perf Week-7.51%
Market Cap5.34B Forward P/E12.53 EPS next Y3.10 Insider Trans0.00% Shs Float136.31M Perf Month-8.42%
Income366.20M PEG0.50 EPS next Q0.50 Inst Own96.30% Short Float7.84% Perf Quarter-17.23%
Sales487.50M P/S10.95 EPS this Y200.60% Inst Trans0.19% Short Ratio7.50 Perf Half Y0.26%
Book/sh2.13 P/B18.23 EPS next Y52.29% ROA28.00% Target Price49.57 Perf Year-7.51%
Cash/sh1.52 P/C25.50 EPS next 5Y31.00% ROE141.90% 52W Range31.36 - 52.98 Perf YTD-3.46%
Dividend- P/FCF18.39 EPS past 5Y40.20% ROI38.10% 52W High-27.18% Beta1.22
Dividend %- Quick Ratio2.20 Sales past 5Y24.80% Gross Margin81.50% 52W Low23.02% ATR1.37
Employees145 Current Ratio2.70 Sales Q/Q11.60% Oper. Margin49.60% RSI (14)34.42 Volatility3.40% 3.27%
OptionableYes Debt/Eq4.25 EPS Q/Q-74.30% Profit Margin75.10% Rel Volume0.61 Prev Close38.82
ShortableYes LT Debt/Eq3.91 EarningsAug 16 BMO Payout0.00% Avg Volume1.42M Price38.58
Recom2.30 SMA20-4.61% SMA50-12.23% SMA200-5.45% Volume874,353 Change-0.62%
Sep-09-22Initiated Morgan Stanley Overweight $50
May-23-22Initiated SVB Leerink Outperform $52
Jun-14-21Initiated Evercore ISI Outperform
May-17-21Initiated SVB Leerink Outperform $56
May-11-21Downgrade Piper Sandler Overweight → Neutral $50 → $48
Jan-21-21Reiterated The Benchmark Company Buy $46 → $59
Dec-17-20Initiated Berenberg Buy $50
Sep-14-20Resumed JP Morgan Overweight $28
Jul-01-20Initiated The Benchmark Company Buy $39
Feb-05-20Upgrade Piper Sandler Neutral → Overweight $18 → $27
Jan-09-20Upgrade BMO Capital Markets Market Perform → Outperform $17 → $24
Jan-08-20Initiated Goldman Buy $24
Nov-05-19Upgrade Barclays Underweight → Equal Weight $17 → $16
Oct-19-18Resumed Piper Jaffray Neutral
May-11-18Downgrade Barclays Equal Weight → Underweight $19
Jan-24-18Initiated Goldman Neutral
Oct-16-17Reiterated Piper Jaffray Overweight $26 → $29
Jan-06-17Downgrade Citigroup Buy → Neutral
Nov-03-16Initiated Deutsche Bank Buy $12
Dec-04-15Initiated Wells Fargo Outperform
Sep-21-22 10:43AM
Sep-08-22 11:30AM
Sep-01-22 08:30AM
Aug-15-22 10:32PM
Aug-10-22 03:13PM
Aug-09-22 06:15PM
Aug-02-22 12:55AM
Jul-26-22 08:30AM
Jul-13-22 09:14AM
Jul-08-22 07:22AM
Jul-06-22 08:08AM
Jul-01-22 01:13PM
Jun-27-22 06:15AM
Jun-21-22 09:13AM
Jun-09-22 11:30AM
Jun-08-22 08:30AM
Jun-07-22 08:30AM
Jun-06-22 06:55AM
May-25-22 09:40AM
May-24-22 08:30AM
May-19-22 12:15PM
May-17-22 10:44AM
May-16-22 09:40AM
May-12-22 09:26AM
May-11-22 09:36AM
May-10-22 05:25PM
May-09-22 09:35AM
May-04-22 08:45AM
May-03-22 02:20PM
Apr-26-22 08:00AM
Apr-22-22 10:22AM
Apr-14-22 01:34PM
Apr-13-22 04:16PM
Apr-06-22 08:24AM
Apr-01-22 08:30AM
Mar-30-22 06:30AM
Mar-25-22 09:47AM
Mar-24-22 11:30AM
Mar-23-22 08:42AM
Mar-22-22 12:22PM
Mar-21-22 08:30AM
Mar-18-22 07:20PM
Mar-17-22 06:00AM
Mar-15-22 04:01PM
Feb-27-22 11:00PM
Feb-23-22 11:31AM
Feb-22-22 05:25PM
Feb-15-22 03:01PM
Feb-09-22 08:00AM
Feb-03-22 08:08AM
Feb-02-22 04:43PM
Jan-31-22 01:38PM
Jan-13-22 09:15AM
Jan-10-22 08:00AM
Jan-04-22 08:00AM
Dec-24-21 11:38PM
Dec-22-21 06:15AM
Dec-17-21 05:46PM
Dec-13-21 04:05PM
Dec-09-21 04:01PM
Dec-07-21 01:51PM
Dec-06-21 11:32AM
Dec-02-21 11:31AM
Dec-01-21 02:21PM
Nov-18-21 09:00AM
Nov-05-21 09:38AM
Nov-03-21 11:42AM
Nov-02-21 05:35PM
Nov-01-21 08:46AM
Oct-28-21 12:10PM
Oct-26-21 04:53PM
Oct-19-21 04:05PM
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LaBarre Michael J.SVP, Chief Technical OfficerFeb 15Option Exercise0.003,3860174,307Feb 17 06:04 PM
LaBrosse NicoleSVP, Chief Financial OfficerFeb 15Option Exercise0.001,25509,478Feb 17 06:03 PM
Torley HelenPresident and CEOFeb 15Option Exercise0.0013,0920594,069Feb 17 06:02 PM
LaBrosse NicoleSVP, Chief Financial OfficerFeb 14Option Exercise0.001,25608,650Feb 14 07:28 PM
Torley HelenPresident and CEOFeb 14Option Exercise0.0028,7290596,102Feb 14 07:27 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 14Option Exercise0.005,7710172,916Feb 14 07:29 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 12Option Exercise0.007,8830169,870Feb 14 07:29 PM
Torley HelenPresident and CEOFeb 12Option Exercise0.0032,7950584,639Feb 14 07:27 PM
LaBrosse NicoleSVP, Chief Financial OfficerFeb 12Option Exercise0.001,38907,900Feb 14 07:28 PM
LaBrosse NicoleSVP, Chief Financial OfficerFeb 10Option Exercise0.002,50307,536Feb 14 07:28 PM
Torley HelenPresident and CEOFeb 10Option Exercise0.0031,2820568,442Feb 14 07:27 PM
LaBarre Michael J.SVP, Chief Technical OfficerFeb 10Option Exercise0.008,1330164,979Feb 14 07:29 PM
Torley HelenPresident and CEONov 08Option Exercise14.6650,000733,000587,160Nov 08 06:22 PM
Torley HelenPresident and CEONov 08Sale39.8250,0001,990,768537,160Nov 08 06:22 PM
MATSUI CONNIEDirectorNov 05Sale40.3832,0001,292,113181,983Nov 05 05:59 PM
LaBarre Michael J.SVP, Chief Technical OfficerOct 12Option Exercise13.108,050105,455156,846Oct 12 07:06 PM
Torley HelenPresident and CEOOct 04Option Exercise14.6650,000733,000587,160Oct 04 07:37 PM
Torley HelenPresident and CEOOct 04Sale40.0950,0002,004,390537,160Oct 04 07:37 PM
LaBarre Michael J.SVP, Chief Technical OfficerOct 01Option Exercise13.1029,450385,795178,246Oct 01 07:32 PM
LaBarre Michael J.SVP, Chief Technical OfficerOct 01Sale39.9329,4501,175,968148,796Oct 01 07:32 PM